Biomedical Engineering Reference
In-Depth Information
Tellis GJ, Stremersch S, Yin E (2003) The international takeoff of new products: the role of
economics, culture, and country innovativeness. Mark Sci 22(2):188-208
The Pharma Letter (1994) French key pharma data for 1993.
http://www.thepharmaletter.com/
fi le/69410/french-key-pharma-data-for-1993.html
.
Accessed 2 June 2011
Urban GL, Carter T, Gaskin S, Mucha Z (1986) Market share rewards to pioneering brands:
an empirical analysis and strategic implications. Manag Sci 32(6):645-659
USA Today, Kaiser Family Foundation, Harvard School of Public Health (2008) The public on
prescription drugs and pharmaceutical companies
Vakratsas D, Kolsarici C (2008) A dual-market diffusion model for a new prescription pharmaceu-
tical. Int J Res Mark 25(4):282-293
Van den Bulte C (2000) New product diffusion acceleration: measurement and analysis. Mark Sci
19(4):366-380
Van den Bulte C, Iyengar R (2011) Tricked by truncation: spurious duration dependence and social
contagion in hazard models. Mark Sci 30(2):233-248
Van den Bulte C, Joshi YV (2007) New-product diffusion with infl uentials and imitators. Mark Sci
26(3):400-421
Van den Bulte C, Lilien GL (2001) Medical innovation revised: social contagion versus marketing
effort. Am J Sociol 106(5):1409-1435
Venkataraman S, Stremersch S (2007) The debate on infl uencing doctors' decisions: are drug
characteristics the missing link? Manag Sci 53(11):1688-1701
Wazana A (2000) Physicians and the pharmaceutical industry: is a gift ever just a gift? J Am Med
Assoc 283:373-380
Windmeijer F, De Laat E, Douven R, Mot E (2006) Pharmaceutical promotion and GP prescription
behavior. Health Econ 15(1):5-18
Wittink DR (2002) Analysis of ROI for Pharmaceutical Promotion (ARPP). Presentation to the
Association of Medical Publications
Search WWH ::
Custom Search